AVEO Enters into Research And Exclusive Option Agreement With Ophthotech For Tivozanib (VEGF inhibitor) For The Treatment Of Ocular Diseases
November 11, 2014 at 06:46 AM EST
AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech ...